| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| 250mg | |||
| Other Sizes |
| Targets |
Transthyretin (TTR). Dichlorophenyl-ABA inhibits TTR amyloid fibril formation and stabilizes TTR tetramers, preventing their dissociation into amyloidogenic monomers.
|
|---|---|
| ln Vitro |
In conditioned medium, dichlorophenyl-ABA (DCPA) inhibits the development of L55P aggregates. Dichlorophenyl-ABA did not exhibit as strong of an inhibitory impact in ultrastructural examination as DFPB and benzoxazole, suggesting that the Y78F mutant may be less responsive to this medication than TTR L55P and V30M [1]. In the plasma of this mutant's carriers, dichlorophenyl-ABA was the most effective stabilizer of V30M tetramers and greatly reduced aggregation in cellular systems. Dichlorophenyl-ABA therefore has promise in treating familial amyloidosis polyneuropathy (FAP) associated with valine 30 (V30M); however, additional phases of therapeutic research are required to overcome its toxicity [1].
Dichlorophenyl-ABA inhibits TTR amyloid fibril formation in vitro. It inhibits aggregate formation by more than 80% in TTR L55P-expressing cells. The compound prevents the formation of L55P aggregates in conditioned media. It is the best stabilizer of V30M tetramers in plasma from carriers of this mutant. |
| ln Vivo |
In vivo, dichlorophenyl-ABA shows potential for treating familial amyloidotic polyneuropathy (FAP) associated with the V30M mutation. As a TTR tetramer stabilizer, it is expected to prevent the dissociation of TTR tetramers into amyloidogenic monomers in vivo, thereby reducing amyloid deposition in tissues. Further drug development is needed to overcome its toxicity.
|
| Enzyme Assay |
In vitro TTR fibril formation assays are used to evaluate the activity of dichlorophenyl-ABA. Purified TTR protein (wild-type or mutant forms such as L55P or V30M) is incubated under conditions that promote fibril formation (low pH or high concentration) in the presence or absence of the compound. Fibril formation is monitored by Thioflavin T fluorescence, turbidity measurements, or electron microscopy.
|
| Cell Assay |
In vitro cell-based assays for dichlorophenyl-ABA evaluate its ability to inhibit TTR aggregation in cells expressing mutant TTR. Cells expressing TTR L55P are treated with the compound, and aggregate formation is assessed using immunofluorescence microscopy or biochemical assays for aggregated TTR. The compound inhibits aggregate formation by more than 80% in this system.
|
| Animal Protocol |
In vivo animal studies for dichlorophenyl-ABA are not extensively documented in the provided literature. Based on its mechanism as a TTR tetramer stabilizer, potential in vivo models include transgenic mouse models expressing mutant human TTR (such as V30M) that develop amyloid deposition. Compound administration and assessment of TTR tetramer stabilization in plasma and tissue amyloid burden would be evaluated.
|
| ADME/Pharmacokinetics |
Dichlorophenyl-ABA has a molecular weight of 282.12 g/mol. It is soluble in DMSO at 100 mg/mL (354.46 mM). Detailed pharmacokinetic parameters such as absorption, distribution, metabolism, and excretion are not extensively reported. Further drug development is needed to address its toxicity.
|
| Toxicity/Toxicokinetics |
Dichlorophenyl-ABA has shown toxicity that needs to be overcome in further drug development stages. Specific toxicity data is not detailed in the provided literature. The compound is classified as a research-grade chemical and is not intended for human use. Standard laboratory safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
Dichlorophenyl-ABA (CAS# 18201-65-5) is an inhibitor of transthyretin (TTR) amyloid fibril formation. It inhibits aggregate formation by >80% in TTR L55P-expressing cells and is the best stabilizer of V30M tetramers in plasma. The compound shows promise for treating familial amyloidotic polyneuropathy (FAP) associated with the V30M mutation, but further development is needed to overcome its toxicity. It has not received FDA approval.
|
| Molecular Formula |
C13H9CL2NO2
|
|---|---|
| Molecular Weight |
282.12
|
| Exact Mass |
281.001
|
| CAS # |
18201-65-5
|
| PubChem CID |
644279
|
| Appearance |
White to light yellow solid powder
|
| Density |
1.47g/cm3
|
| Boiling Point |
420.8ºC at 760mmHg
|
| Flash Point |
208.3ºC
|
| Vapour Pressure |
7.85E-08mmHg at 25°C
|
| Index of Refraction |
1.677
|
| LogP |
4.508
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
18
|
| Complexity |
291
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
FNGSQOJHNAYHAT-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C13H9Cl2NO2/c14-8-5-9(15)7-10(6-8)16-12-4-2-1-3-11(12)13(17)18/h1-7,16H,(H,17,18)
|
| Chemical Name |
2-(3,5-dichloroanilino)benzoic acid
|
| Synonyms |
Dichlorophenyl-ABA; Dichlorophenyl ABA
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~354.46 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5446 mL | 17.7230 mL | 35.4459 mL | |
| 5 mM | 0.7089 mL | 3.5446 mL | 7.0892 mL | |
| 10 mM | 0.3545 mL | 1.7723 mL | 3.5446 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
